2 super growth stocks I’d buy with £5,000 today

Just £5,000 could help you make a fortune with these super growth stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Feeding the world’s ever-growing population is big business, and with the number of humans on this planet set to hit 9bn by 2050, the food production industry has its work cut out.

One play on this trend is the AIM-traded producer of nutrition, breeding and health products for the global aquaculture industry Benchmark (LSE: BMK).

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Building for the future 

For the past two decades, Benchmark has been in investment mode, spending heavily to increase its global footprint and re-investing all of the cash generated from its fledgeling operations back into the business. It now looks as if all this hard work is starting to pay off.

For the six months ended 31 March, adjusted earnings before interest, tax, depreciation and amortisation jumped 91% to £6.3m while adjusted profit before tax hit £4.4m. Revenue for the period grew 9% to £75.7m.

That being said, Benchmark is still ploughing funds back into growth. The firm recently completed a £17m commercial-scale fish vaccine manufacturing site in Braintree and its disease-free fish egg production facility in Norway expects to reach full capacity by 2019. Meanwhile, the group recently tapped shareholders for £12.2m to fund a 49% interest in a “strategically important Chilean JV” giving it a large presence in Chile, the world’s second-largest salmon market.

In my opinion, management is heading in the right direction by prioritising growth over profit at this stage. The global aquaculture market is expected to grow by 5% per annum to reach a market size of $219bn by the year 2022, and it would be silly for Benchmark not to make the most of the market expansion. 

Unfortunately, as the company continues to invest, City analysts are expecting losses to continue for the next few years, but over time, Benchmark’s efforts should really pay off, and I wouldn’t be surprised if a larger competitor buys out the enterprise and its technology before it has a chance to break even.

Follow the money 

Unlike Benchmark, Hikma Pharmaceuticals (LSE: HIK) is already profitable, but growth has hit the rocks in recent years thanks to rising competition and the firm’s own mistakes.

Still, now Hikma is in recovery mode, and it looks as if the business has the unreserved backing of its management. CEO Sigurdur Olafsson recently splashed out £262k to snap up 20,000 shares in the company and was shortly followed by Chief Scientific Officer Surendera Tyagi who spent £20k.

Analysts have soured on Hikma recently because the launch of what was supposed to be a blockbuster generic version of Advair, GlaxoSmithKline’s money-spinning respiratory medicine, has been held back by the US drugs regulator the FDA.

This was supposed to be one of the company pillars of growth in 2018 and 2019, but it now looks as if there will be no approval until at least 2020. In the meantime, the City believes Hikma’s growth will be sluggish with earnings growth of just 5% is pencilled in for this year.

Nonetheless, as with Benchmark, I believe that over the long term, Hikma’s growth will return as the world’s ever-expanding population demands access to more affordable healthcare. The stock might not look cheap today, trading at 20 times forward earnings, but the potential opportunity available to the business over the long term is clear.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Rupert Hargreaves owns shares in GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Social media and digital online concept, woman using smartphone
Investing Articles

Will Lloyds shares recover in 2022?

Lloyds shares have struggled this year and the looming recession won't help. But I'd still buy them today.

Read more »

Two hands holding champagne glasses toasting each other with Paris in the background
Investing Articles

Can the stock market make me rich even now?

Here are three ways I'm coping with the stock market's recent bout of weakness and aiming to build wealth in…

Read more »

Cogs turning against each other
Investing Articles

3 top investment trusts to buy right now

Investment trusts offer a wide range of options for investors. And in troubled times, they provide some safety through diversification…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Why hasn’t the FTSE 100 crashed in 2022?

The catastrophic events of 2022 have left investors around the globe fearing the worst for stock markets. And some have…

Read more »

Trader on video call from his home office
Investing Articles

2 inflation-resistant FTSE 100 stocks to buy today

Soaring inflation could dent my returns if I don't take care. Here are two top inflation-resistant FTSE 100 stocks I'd…

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

Why a bear market is an investor’s best friend

A bear market can certainly be scary. But any investor tempted to sell might benefit by looking at Warren Buffett's…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

The Rolls-Royce share price could be stuck below £1 for a while. Should I buy?

The Rolls-Royce share price has been trading at penny stock levels since April. Could the stock be a bargain at…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

I’m aiming to make £45,000 in passive income with UK shares and never work again!

Investing regularly in UK shares can generate a substantial passive income over the long run. Zaven Boyrazian demonstrates how.

Read more »